BLFS
BioLife Solutions Inc
37.70$
-0.9%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +38.9% | -43.7% | +7.0% | +55.1% | -111.2% | – | +6.2% | +10.4% | -33.1% | +46.4% | +3.5% | – | |
| – | +102.8% | -73.6% | +5.1% | +34.7% | -233.4% | – | +10.2% | +12.9% | -39.8% | +65.2% | +0.9% | – | |
| – | -22.9% | +32.3% | +7.9% | +65.1% | -62.1% | +90.9% | +4.1% | +9.1% | -29.3% | +37.3% | +5.0% | – | |
| – | +17.7% | -19.7% | -42.6% | +1.0% | -47.1% | +103.1% | +23.4% | -0.4% | -97.6% | +3,915.2% | +11.6% | – | |
| – | +19.9% | -19.8% | -10.4% | +21.8% | -42.0% | +74.6% | -0.9% | +5.9% | -12.6% | +15.7% | -12.4% | – | |
| – | -18.4% | -30.7% | -6.6% | +61.0% | -70.5% | +147.0% | +94.5% | -45.5% | -61.9% | +153.5% | -4.6% | – | |
| – | – | – | – | – | – | -187.9% | – | – | – | -99.5% | +6,181.5% | – | |
| – | +12.9% | -59.2% | +74.4% | -26.0% | -56.6% | – | – | -25.7% | -70.1% | – | – | – | |
| – | – | – | – | – | – | -128.1% | – | – | +378.2% | -62.9% | +120.6% | – | |
| – | -137.4% | – | -94.1% | -2,900.0% | – | – | +800.0% | -34.9% | -311.0% | – | -68,408.1% | – | |
| – | – | – | – | – | – | -103.6% | – | – | +469.2% | -66.4% | +3,703.0% | – | |
| – | – | – | – | -19.2% | +691.0% | -97.5% | -8,732.5% | – | +293.1% | -85.2% | +301.1% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.